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ABSTRACT  250 /250 
Background: There is strong public belief that polyunsaturated fats protect against and 
ameliorate depression and anxiety.   
 
Aims: To assess effects of increasing omega-3, omega-6 or total polyunsaturated fat on 
prevention and treatment of depression and anxiety symptoms.   
 
Method: We searched widely (Central, Medline, Embase to April 2017, trials registers to 
September 2016, ongoing trials updated August 2019), including  trials of adults with or 
without depression or anxiety, randomised to increased omega-3, omega-6 or total 
polyunsaturated fat for ≥24 weeks, excluding multi-factorial interventions. Inclusion, data 
extraction and risk of bias were assessed independently in duplicate, authors contacted for 
further data. We used random-effects meta-analysis, sensitivity analyses, subgrouping and 
GRADE assessment.   
 
Results: We included 31 trials assessing effects of long-chain omega-3 (n=41,470), one of 
alpha-linolenic acid (n=4837), one of total polyunsaturated fat (n=4997), none of omega-6. 
Meta-analysis suggested increasing long-chain omega-3 probably has little or no effect on 
risk of depression symptoms (RR 1.01, 95% CI 0.92-1.10, I2 0%, median dose 0.95g/d, 
duration 12 months) or anxiety symptoms (SMD 0.15, 95% CI 0.05-0.26, I2 0%, median 
dose 1.1g/d, duration 6 months, both moderate-quality evidence).  Evidence of effects on 
depression severity and remission in those with existing depression were unclear (very low-
quality evidence). Results did not differ by risk of bias, omega-3 dose, duration or nutrients 
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replaced. Increasing alpha-linolenic acid by 2g/d may increase risk of depression symptoms 
very slightly over 40 months (number needed to harm=1000).  
 
Conclusions: Long-chain omega-3 supplementation probably has little or no effect in 
preventing depression or anxiety symptoms.  
 
Declaration of interests: KHOD, OFJ, PB, SH, ASA and LH had financial support from 
WHO via UEA for the submitted work; LH and AA were funded to attend WHO meetings 
and present review results. No other conflicts of interest.  
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Relevance statement:  
Many adults take omega-3 supplements to improve their mental health.  Our 
comprehensive systematic review and meta-analysis included 31 trials (41470 participants) 
assessing long-term effects of long-chain omega-3 (LCn3).  Meta-analysis suggested 
increasing LCn3 probably has little or no effect on risk of depression or anxiety symptoms 
(moderate-quality evidence). Results did not differ by risk of bias, omega-3 dose, duration 
or nutrients replaced. Physicians should not recommend omega-3 supplements for 
reducing depression or anxiety risk. Long-term utility of LCn3 in existing depression is 
unclear.   
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Background  
There is a common belief that increasing omega-3 intake may prevent and treat both 
depression and anxiety, and in the US long-chain omega-3 intakes are greater from dietary 
supplements (0.72 g/d EPA and DHA) than foods (0.41 g/d).(1)  Globally depressive 
disorders are the third most common cause of years lived with disability in women, and fifth 
in men, while anxiety disorders are eighth and fifteenth respectively.(2) Lifetime prevalence 
of anxiety disorders is 10-17%, mood disorders 10-16%,(3, 4) with higher rates in people 
with long-term conditions.(5-7)  
 
The aetiological theories of depression and anxiety suggest concurrent alterations in brain 
chemistry, environmental stressors, and genetic predisposition. Polyunsaturated fatty acids 
(PUFAs), including long-chain omega-3 (LCn3, mostly from fish), alpha-linolenic acid (ALA, 
a plant-based omega-3) and omega-6 fatty acids (mostly from vegetable oils) have roles in 
the synthesis, release, reuptake, degradation and binding of neurotransmitters, and in 
neural structure and function.(8-10) Neuronal cell membranes contain high levels of 
docosahexaenoic acid (DHA, an LCn3). Observational research suggests correlations 
between low omega-3 or fish consumption and depression,(11, 12) while people with social 
anxiety disorder have lower erythrocyte membrane omega-3 and higher omega-6/omega-3 
ratios than controls, and negative correlations between omega-3 levels and anxiety scores 
have been observed.(13) Thus, increasing omega-3 intake and/or reducing omega-6 
intakes may have anti-depressant and anxiolytic effects,(9, 14) but reverse causation is 
highly feasible in that poor mental health may lead to lower quality dietary intake.  
 
We aimed to assess effects of increasing LCn3, ALA, omega-6 or total PUFA on 
depression and anxiety in randomised controlled trials of at least 6 months duration. 
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Method 
This systematic review and meta-analysis is part of a series of systematic reviews 
commissioned by WHO assessing health effects of omega-3, omega-6 and total PUFA.  
(15-23)  Its protocol was registered (PROSPERO: CRD42017056092).  Specific methods 
for this review are discussed below, detailed methods for the review series are reported 
elsewhere, including detailed search strategies, list of variables data extracted, and the 
wider database of trials.(22)  
 
Criteria for considering studies for this review 
Types of studies 
We included only randomised controlled trials (RCTs) of at least 6 months (24 weeks) 
duration. The 24 week cut-off reflects metabolic studies suggesting 6 months as the 
minimum duration of supplementation required to ensure equilibration of LCn3 into most 
body compartments, including the brain.(24) 
 
Types of participants 
Participants in included studies had to be adults (18+ years) who were not pregnant or 
seriously ill.  Participants could have a current or previous diagnosis of clinical depression 
or anxiety, but this was not necessary. 
 
Types of intervention and comparison 
Studies were included where they compared higher with lower omega-3, omega-6 and/or 
total PUFA intakes.  The intervention could consist of advice, foodstuffs or oral supplements 
(oil, capsules, or provided foodstuffs) that aimed to alter omega-3, omega-6 and/or total 
PUFA intake, or (if no specific aim was stated) achieved a change of ≥10% of baseline 
intake. Studies were excluded if they examined multiple risk factor interventions on lifestyle 
or dietary factors other than PUFA. Interventions had to be compared with usual diet, no 
advice, no supplementation or placebo (as appropriate) or compared raised versus lowered 
PUFA intake over ≥24 weeks.  
 
Types of outcome measures 
Included trials assessed at least one of the primary outcomes (even where these outcomes 
were not fully reported).  
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Primary outcomes:  
 Risk of depression or anxiety symptoms assessed using formal diagnosis or an 
appropriate scale, dichotomised to give risk of depression or anxiety in participants 
without depression or anxiety at baseline 
 Severity of depression or anxiety symptoms as a continuous scale in participants 
with or without existing depression. 
 Severity of depression or anxiety, or relapse, in those with depression at baseline.  
Assessment of depression or anxiety did not have to be the main study goal.  
 
Secondary outcomes: 
 Social participation 
 Quality of life 
 Carer stress 
 Healthcare and patient costs 
 Adherence 
 Fidelity 
 Adverse events 
 Withdrawal rates 
 Withdrawals due to non-compliance, lack of efficacy and/or side effects. 
 Psychosis, suicidality, suicide and self-harm 
 
Secondary outcomes were data extracted from included studies.  
 
Search methods for identification of studies 
We searched Cochrane Central, Medline and Embase to 27th April 2017, ClinicalTrials.com 
and the World Health Organization International Clinical Trials Registry Platform to 
September 2016, and reassessed all ongoing trials in August 2019. Searches were not 
limited by language or publication date. We checked included trials of relevant systematic 
reviews, and wrote to authors of included studies for additional studies and trial data 
(including unpublished summary outcome data). Full search methods and full text of 
electronic search strategies are reported in full in our methodology paper.(22) 
 
Data collection 
Study inclusion, data extraction and assessment of risk of bias were conducted 
independently in duplicate, disagreements resolved by discussion or a third reviewer.  
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Assessment of risk of bias in included studies 
We assessed Cochrane risk of bias domains,(25) and also assessed risk from compliance 
problems and attention bias specifically for our reviews. (15-23)  Included trials were judged 
at low summary risk of bias where randomisation, allocation concealment, blinding of 
participants, personnel and outcome assessors were adequate (all other trials were at 
moderate or high risk of bias).  
 
Data synthesis 
Main analyses assessed effects of increasing omega-6, LCn3, ALA and mixed PUFA on 
primary outcomes using random effects meta-analysis (as dietary interventions are 
heterogeneous by their nature (26)) with risk ratio or mean differences in Review Manager 
5.3.(27) Where different scales could be combined the direction of scales was standardised 
(so lower scores signified lower levels of depression or anxiety) and combined using 
standardised mean differences.  
 
Sensitivity analyses 
Pre-specified sensitivity analyses of primary outcomes included fixed effects meta-analysis, 
limiting analysis to studies at low summary risk of bias, limiting to studies at low risk for 
compliance issues, and limiting to trials randomising ≥100 participants.  
 
Subgroup analysis and investigation of heterogeneity 
Pre-specified subgroup analyses were conducted for primary outcomes with ≥8 included 
studies by intervention type, replacement, dose, duration, baseline depression risk (high 
risk - people with clinically diagnosed depression and/or anxiety using any diagnostic 
criteria, medium risk - with depression or anxiety risk factors such as a long-term conditions 
or low risk – all other populations) and anti-depressant or anti-anxiety medication use in 
≥50% participants.(22) We planned to sub-group by severity of baseline depression and 
combined anxiety/ depression diagnosis, but only two trials included participants with 
diagnosed depression (28), and by baseline intake of omega-3, omega-6 or total PUFA, but 
this information was not available in most trials so was not attempted.  
 
We assessed heterogeneity between trials using I2, and small study bias using funnel plots, 
the Harbord and Peters (for dichotomous data) or Egger (for continuous data) tests (25, 29) 
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where there were ≥10 included trials, comparison of random and fixed effects analyses and 
knowledge of missing data.  
 
Interpretation of findings 
Effect sizes were interpreted as agreed with the WHO Nutrition Guidance Expert 
Advisory Group (NUGAG) Subgroup on Diet and Health (who commissioned this review 
as part of a set of work to underpin their dietary guidance)and pre-specified for this set of 
reviews.(22)  RR <0.92 or >1.08 was considered a relevant clinical effect (RR 0.92 to 
1.08 was considered “little or no effect”), while mean difference between arms of ≥10% 
of baseline was required for a relevant clinical effect for continuous measures. Outcome 
data were interpreted using GRADE assessment, drafted by LH then discussed and 
agreed with WHO NUGAG as elaborated elsewhere.(22)  Where GRADE suggested 
data of very low-quality we did not interpret effect sizes.  Where data were of low-quality 
we used the term “may”, moderate-quality evidence warranted “probably” in describing 
effect sizes.  
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Results 
The search strategy for the wider set of reviews found 364 RCTs (reported in 1020 papers) 
of omega-3, omega-6 or total PUFA with a duration of at least six months.(22) From this set 
32 RCTs that assessed outcomes of interest were included in this review (Supplementary 
Figure 1, for more detail see methods paper).(22) Systematic review results, including 
sensitivity analyses and subgrouping, are provided briefly here and in more detail in 
Supplementary Text 1, in the Supplementary file. 
 
Characteristics of included studies 
Characteristics of included studies and risk of bias are detailed in Table 1 and in more detail 
in our database paper (20). Thirty one trials (41,470 participants) assessed effects of 
LCn3,(28, 30-61) one assessed effects of ALA (4837 participants),(30) and one assessed 
effects of higher total PUFA (4997 participants).(62) No trials assessed effects of omega-6 
on depression or anxiety. 
 
Participants were recruited with chronic illness or risk factors in 17 trials; memory deficit, 
cognitive impairment or Alzheimer’s disease in six; mental health problems in four; and 
healthy participants in 5 trials.  
 
Of the 31 LCn3 trials, most gave supplementary capsules or medicinal oils, two used 
supplemental foods (enriched margarine and fish sausages);(30, 40) one provided dietary 
advice;(57) and one a combination.(43) The ALA trial provided enriched margarine,(30) and 
the PUFA trial dietary advice plus nuts.(62) LCn3 doses ranged from 300-3360mg/d 
EPA+DHA,(28, 54) 12 trial arms assessed doses of ≤1000mg/d, 13 arms 1001-2000mg/d, 
and seven arms >2000mg/d EPA+DHA. Control groups received olive, corn or sunflower 
oils, other fats, other 'inert' or ill-defined substances, different dietary advice, foods without 
omega-3 enrichment, or nothing.  
 
Risk of bias of included studies 
Risk of bias is itemised by domain and study in Figure 1. Of the 32 RCTs (33 comparisons 
including 46,467 randomised participants) twelve were judged to be at low summary risk of 
bias,(30, 31, 34, 38, 43, 45, 48, 50, 51, 55, 56, 59, 60) including twelve LCn3 comparisons, 
and the single ALA assessment (Figure 1). Trial authors provided some response to 
attempted contact for 16 trials.   
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Effects of increasing omega-3, omega-6 or total PUFA on risk of depression symptoms 
Thirteen RCTs (randomising 26,528 participants, reporting 1355 people developing 
depression symptoms, median dose 0.95g/d, range 0.4 to 3.4g/d, median duration 12 
months, range 6 to 89 months) suggested little or no effect of increasing LCn3 on risk of 
depression symptoms (RR 1.01, 95% CI 0.92 to 1.10, I2 0%, Figure 2). This did not differ in 
sensitivity analyses by summary risk of bias, fixed effects or study size, though retaining 
only trials with good compliance suggested increased depression risk with increased LCn3 
(RR 1.16, 95% CI 0.99 to 1.36, I2 0%, Supplementary Table 1). Over 90% of meta-analytic 
weight came from three trials that assessed depression symptoms dichotomously using the 
Center for Epidemiologic Studies Depression Scale (CESD, score ≥16),(31) Becks 
Depression Inventory (BDI-II, score ≥14),(50) and General Health Questionnaire (GHQ-30, 
≥5).(51) In other trials depression events were based on Geriatric Depression scores (GDS-
15, >10), reported as adverse events or were unclear. There was no suggestion of 
publication bias in visual inspection of the funnel plot, or using statistical tests (Harbord test 
p=0.27, Peters test p=0.29), and no suggestion of heterogeneity. Effects did not differ by 
intervention type, replacement nutrients, or LCn3 dose, but subgrouping suggested 
increased depression risk with LCn3 in healthy adults, and little or no effect in those with 
comorbid illnesses. One LCn3 trial recruited only participants with current depression in 
which ≥50% took antidepressants.(28) As pre-specified LCn3 dose subgroupings did not 
divide included trials effectively, post-hoc we re-ran even LCn3, EPA and DHA dose 
subgroupings. There was no suggestion of LCn3 dose effects (test for subgroup differences 
p=0.98), EPA (p=0.13) or DHA (p=0.87) effects, Supplementary Figures 2-4.  
 
GRADE assessment suggests that increasing LCn3 probably has little or no effect on risk of 
depression symptoms (moderate-quality evidence, downgraded once for imprecision, 
Supplementary Table 2). This was confirmed in data on depression symptoms analysed as 
continuous data in 15 trials including participants not selected for depression at baseline 
(for details see Supplementary Text 1 and Supplementary Table 2).  
 
Data were limited from trials of ALA and total PUFA on depression (Supplementary Tables 
3 and 4). We found no data from trials of omega-6 (Figure 2). GRADE suggests that 
increasing ALA may increase risk of depression symptoms very slightly (NNH 1000, low-
quality evidence, downgraded twice for imprecision) and effects of increasing total PUFA on 
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depression risk are unclear as the evidence is of very low-quality (downgraded once each 
for risk of bias, indirectness and inconsistency, Supplementary Tables 5 and 6). 
 
Effects of increasing omega-3, omega-6 or total PUFA on depression severity and remission 
in those with existing depression 
A single small trial assessed effects of LCn3 for 6 months in poor Iranian men with mild or 
moderate depression at baseline(28), and found that GDS score fell by >10% of baseline 
(suggesting reduced depression severity) in the higher vs lower LCn3 arm (MD -0.94, 95% 
CI -2.27 to 0.39, 61 participants). A further small study (n=24) included participants with 
Parkinson’s Disease,(53) some of whom were depressed at baseline, and reported on 
remission, suggesting more remission in those on higher LCn3 (Supplementary Table 1). 
GRADE assessment suggests that effects of increasing LCn3 on risk of depression severity 
and risk of remission in those with existing depression are unclear as the evidence was of 
very low-quality (depression severity downgraded twice for risk of bias, once for 
inconsistency, risk of remission ARR 0.58, downgraded once for risk of bias and twice for 
indirectness, Supplementary Table 2). 
 
No trials of ALA, omega-6 or total PUFA included participants with depression at baseline.  
 
Effects of increasing omega-3, omega-6 or total PUFA on risk of anxiety symptoms, severity 
and remission 
Data were limited from trials of LCn3 assessing anxiety symptoms (Supplementary Tables 
1 and 2). One study provided data on effects of LCn3 on risk of anxiety (RR 1.00, 95% CI 
0.32 to 3.10), none on remission. Five studies assessed effects of increasing LCn3 on 
anxiety symptoms using four different scales (SMD 0.15, 95% CI 0.05 to 0.26, I2 0%, 1378 
participants, and no included studies were at low summary risk of bias, Figure 3). No 
studies provided data on effects of ALA, omega-6 or total PUFA on anxiety incidence, 
remission or symptoms. GRADE assessment suggests that increasing LCn3 probably has 
little or no effect on anxiety symptoms (moderate-quality evidence, downgraded once for 
risk of bias, Supplementary Table 2). 
 
Secondary outcomes 
Data on secondary outcomes are reported in Supplementary Text 1 and Supplementary 
Tables 7 and 8. Data were found on quality of life, carer stress, suicidality, adverse events, 
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drop outs and drop outs due to adverse events, but data were sparse, often poorly reported 
and may suffer from reporting bias. We did not identify any clear harms or benefits of 
interventions for these outcomes. We have formally systematically reviewed effects of 
omega-3, omega-6 and total PUFA on cancer, diabetes, cognition, inflammatory bowel 
disease, cardiovascular disease, functional outcomes, mortality, adiposity and lipids in 
sister reviews, so these outcomes are not reported here. (15-23)   
 
Discussion 
GRADE assessment of our meta-analytic data suggests that increasing LCn3 probably has 
little or no effect on risk of depression or anxiety symptoms in those without depression or 
anxiety at baseline (moderate-quality evidence), but effects on depression severity and risk 
of remission in depression were unclear. Increasing ALA may increase risk of depression 
symptoms very slightly (1000 people would need to increase their ALA intake for one 
additional person to develop depression symptoms). Data on other outcomes and effects of 
increasing omega-6 and total PUFA were missing or of very low quality.   
 
Strengths and Limitations 
Strengths of this review include our very broad search of long-term trials that assessed 
effects of omega-3, omega-6 or total PUFA on any outcomes,(22) and contact with many 
trial authors enabling us to include previously unpublished data. Evidence for the lack of 
impact of LCn3 on risk of depression symptoms comes from a broad range of trials, across 
thousands of men and women with diverse health status and depression risk, including 
large, long-term trials with low summary risk of bias. The broad set of trials also allowed 
thorough assessment of publication bias. We have used subgrouping to assess potential 
effects of LCn3, EPA and DHA dose, study duration (much of our data came from large 
trials of 3 or more years duration) and replacement of other nutrients (including omega-6, 
monounsaturated and saturated fats) on depression symptoms. Increasing LCn3, EPA or 
DHA dose or trial duration or altering nutrients replaced by LCn3 do not improve 
effectiveness of LCn3 on risk of depression symptoms.  
Limitations include lack of information within trials on baseline LCn3 intake.  Baseline intake 
of LCn3 could alter effectiveness of LCn3 supplementation, as increasing LCn3 would be 
more likely to be effective in those with poor baseline intakes. However where trials 
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reported baseline LCn3 intake or status they did so in ways that are not comparable across 
trials (e.g. oily fish intake, erythrocyte membrane EPA, plasma LCn3), so we were unable to 
assess effects by baseline LCn3 status or intake. While available data did not allow us to 
assess effects by omega-3/omega-6 ratio there was no suggestion of greater effects when 
omega-3 replaced omega-6, downplaying the importance of this ratio in depression and 
anxiety. The variety of methods of assessment of depression and anxiety symptoms, and 
limited clinical diagnoses of depression or anxiety (relying on scales of symptoms) may also 
limit clinical interpretation. However, these are the best data available on prevention of 
depression and anxiety, there are no previous systematic reviews of prevention and our 
collation of a broad database of all long-term trials of omega-3, omega-6 and total PUFA 
has allowed assessment of effects that are otherwise unpublished and inaccessible.(22) 
We carried out SMD analysis and reported effects in the single most common scale.  
 
Comparison with other research 
The MooDFOOD trial randomised participants to 1.4g/d LCn3 plus additional micronutrients 
or placebo and found no effect on diagnosis of major depressive disorder after 1 year in 
1025 overweight adults with subsyndromal depressive symptoms.(63)  This trial is not 
included in our systematic review as the intervention was multifactorial (effects of LCn3 
cannot be separated out) but confirms our review findings that LCn3 supplementation does 
not help to prevent depression.  We found no previous systematic reviews of randomised 
controlled trials on effects of omega-6 or total PUFA, none separated out effects of ALA, 
and none assessed effects on prevention of depression. Systematic reviews on anxiety 
have included trials of very short duration and without controls.(64)  
Given that humans require at least 6 months to equilibrate fatty acids throughout our bodies 
when changes to LCn3 intake occur,(24) we were surprised to find only two small trials of 
LCn3 with a duration of at least 24 weeks that included participants with depression at 
baseline, to enable assessment of effects on depression severity and remission. As 
depression and anxiety are commonly recurring illnesses, longer term health effects are 
crucial to understand, and we assumed we would find trials of polyunsaturated fats 
alongside effective antidepressants or anxiolytics compared with placebo and the same 
effective antidepressant or anxiolytic.  None of our included trials clearly assessed dietary 
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fats in combination with medications for depression or anxiety, which could potentiate 
effectiveness. 
Shorter term trials of omega-3 fats have been extensively reviewed.  For example, a 
previous high quality Cochrane systematic review of shorter trials of LCn3 in people with 
depression suggested small to modest non-clinically beneficial effects but queried risk of 
bias and publication bias in this dataset. (14) However, another systematic review of trials 
in major depression suggested efficacy at higher EPA doses and alongside 
antidepressants. (65) Like the Cochrane review, which also used GRADE assessment, (14) 
we found that evidence of effects of LCn3 on depression severity and remission were of 
very low-quality.  Other recent systematic reviews of effects of omega-3 in people with 
existing depression have concluded that there were “mixed findings” in older adults, 
suggesting that more high-quality, large-scale RCTs are needed (66), in call for trials in 
people with diagnosed depression and of longer duration (67), and with a suggestion that 
combined EPA and DHA are of (non-significant) benefit  in women (based on fewer than 
400 participants) (68).   
LCn3 was mainly provided in supplementary form, so while there was no suggestion of 
different effects in trials of dietary advice or where oily fish was provided to participants 
compared with trials of LCn3 supplements, effects of dietary fish may differ (as dietary fish 
replaces other foods, and includes a wide range of additional nutrients including protein, 
selenium, iodine, calcium and magnesium).  
While LCn3 and ALA may protect against depression and anxiety in select individuals due 
to specific genetic, dietary and/or metabolic characteristics, LCn3 and ALA will be harmful 
in other selected individuals. This systematic review suggests that any such benefits and 
harms are balanced, and that there will be no overall benefits on depression and anxiety 
symptoms of increasing LCn3 in general populations.  
 
Implications for practice 
Many adults take omega-3 supplements to improve their mental health.  Our 
comprehensive systematic review and meta-analysis suggested that taking LCn3 
supplements probably has little or no effect on risk of depression or anxiety symptoms 
(moderate-quality evidence).  Results did not differ by risk of bias, omega-3 dose, duration 
or nutrients replaced. Effects on depression severity and remission were unclear (very low-
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quality evidence). Physicians should not recommend omega-3 supplements for reducing 
depression or anxiety risk, and evidence of effectiveness in existing depression is of very 
low-quality.  
 
Research Implications 
Further methodologically strong long-term trials (that focus on robust randomisation, 
allocation concealment, and blinding of participants, trial staff and outcome assessors, as 
well as adequately checking compliance in both the intervention and control arms) are 
needed to drive practice in people with existing depression and anxiety.   
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Figure 1: Itemised risk of bias for included RCTs  
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Figure 2. Meta-analysis of trials randomising to higher vs lower LCn3, ALA, omega-3 and 
total PUFA intake and reporting risk of depression symptoms 
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Figure 3.  Meta-analysis of trials randomising to higher vs lower LCn3 intake and assessing 
anxiety  
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Study Population, country Intervention  Comparison Participants 
randomised 
Trial 
Duration 
AlphaOmega – 
Kromhout 2010 
ALA(30, 69) 
60-80 year olds with previous 
myocardial infarction, Netherlands 
ALA-rich supplementary 
margarine, 2g ALA/d 
ALA vs MUFA 
 
2409 int, 
2428 cont 
3.3 years 
AlphaOmega – 
Kromhout 2010 EPA & 
DHA(30, 69) 
60-80 year olds with previous 
myocardial infarction, Netherlands 
EPA & DHA-rich supplementary 
margarine, 0.24g/d EPA & 
0.16g/d DHA 
LCn3 vs 
MUFA 
2404 int, 
2433 cont 
3.3 years 
AREDS2 2014(31) 50-85 year olds at high risk of 
progression to advanced age-
related macular degeneration, 
USA 
EPA & DHA supplement, 0.65g/d 
EPA & 0.35g/d DHA 
LCn3 vs nil 2157 int, 
2046 cont 
5 years 
ASCEND 2018(59) Patients with diabetes, without 
apparent vascular disease, UK 
EPA & DHA supplement, 0.46g/d 
EPA & 0.38g/d DHA 
LCn3 vs 
MUFA 
7740 int, 
7740 cont 
7.4 years 
Chiu 2008(32) Older adults with Alzheimer's 
Disease or Mild Cognitive 
Impairment, Taiwan 
EPA & DHA supplement, 1.08g/d 
EPA & 0.72g/d DHA 
LCn3 vs 
MUFA 
24 int, 22 
cont 
0.5 years 
DART2 Burr 2003(70) Men treated for angina, UK Dietary fish advice or EPA 
supplement, 2.4g/week EPA  
LCn3 vs nil 1571 int, 
1543 cont 
3-9 
years 
Derosa 2016(34) Overweight/obese Caucasians 
with impaired fasting glucose (IFG) 
or impaired glucose tolerance 
(IGT), Italy 
EPA & DHA supplement, 0.83g/d 
EPA & 1.57g/d DHA 
LCn3 vs non-
fat 
138 int, 143 
cont 
1.5 years 
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DIPP – Tokudome 
2015(35) 
Patients previously 
polypectomised for colorectal 
tumours, Japan 
Dietary advice to increase oily fish 
& ALA-rich oil & EPA & DHA 
supplement, unclear EPA & DHA 
LCn3 vs non-
fat 
104 int, 101 
cont 
2 years 
DO IT - Einvik 
2010(36) 
Elderly men with long standing 
dyslipidaemia or hypertension, 
Norway 
EPA & DHA supplement, 0.84g/d 
EPA & 0.48g/d DHA 
LCn3 vs n6 282 int, 281 
cont 
3 years 
EPE-A – Sanyal 
2014(37) 
People with non-alcoholic 
steatohepatitis (NASH) & non-
alcoholic fatty liver disease 
(NAFLD), USA 
EPA supplement, 0.9g/d EPA  LCn3 vs 
unclear 
86 int, 82 
cont 
1 year 
EPOCH – Danthiir 
2011(38) 
Healthy older adults with no 
cognitive impairment, Australia 
EPA & DHA supplement, 0.6g/d 
EPA & 1.72g/d DHA 
LCn3 vs 
MUFA 
195 int, 196 
cont 
1.5 years 
Ferreira 2015(39) Adults with Huntington's disease, 6 
European countries 
EPA supplement, 2.0g/d EPA  LCn3 vs 
unclear 
147 int, 143 
cont 
0.5 years 
Hashimoto 2016(40) Healthy older people, Japan EPA & DHA supplement, 0.18g/d 
EPA & 0.81g/d DHA 
LCn3 vs 
MUFA 
43 int, 32 
cont 
1 year 
Jackson 2016(41) Healthy adults with subjective 
memory deficit, UK 
EPA & DHA supplement, 0.13g/d 
EPA & 0.90g/d DHA 
LCn3 vs 
MUFA 
33 int, 32 
cont 
0.5 years 
Lee 2012(42) People aged ≥60 years, low to 
middle socioeconomic status, 
Malaysia 
EPA & DHA supplement, 0.15g/d 
EPA & 0.43g/d DHA 
LCn3 vs n6 18 int, 18 
cont 
1 year 
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MAPT – Vellas 
2017(60) 
People aged ≥70 years with 
memory complaint, IADL limitation 
or slow gait speed, France & 
Monaco 
EPA & DHA supplement, 0.23g/d 
EPA & 0.80g/d DHA 
LCn3 vs non-
fat 
 
840 int, 840 
cont 
3 years 
MEMO – Van de Rest 
2008(61) 
Independently living people aged 
≥65 years, Netherlands 
EPA & DHA supplement, 1.09g/d 
EPA & 0.85g/d DHA or 0.23g/d 
EPA & 0.18g/d DHA 
LCn3 vs 
MUFA 
196 int, 106 
cont 
0.5 years 
MIDAS – Yurko-Mauro 
2010(45) 
Healthy older people with 
subjective memory complaints, 
USA 
DHA supplement, 0.90g/d DHA LCn3 vs n6 242 int, 243 
cont 
0.5 years 
NEURAPRO – 
McGorry 2017(46) 
Young people at ultra-high risk for 
psychotic disorders, Australia, 
Switzerland, Germany, China, 
Austria, Singapore, Netherlands 
EPA & DHA supplement, 0.84g/d 
EPA & 0.56g/d DHA 
LCn3 vs non-
fat 
153 int, 151 
cont 
0.5 years 
OFAMS – Torkildsen 
2012(47) 
People with relapsing remitting 
multiple sclerosis, Norway 
EPA & DHA supplement, 1.35g/d 
EPA & 0.85g/d DHA 
LCn3 vs n6 46 int, 46 
cont 
0.5 years 
OFFER – Pawelczyk 
2015(48) 
People with first episode of 
schizophrenia aged 16–35, Poland 
EPA & DHA supplement, 1.32g/d 
EPA & 0.88g/d DHA 
LCn3 vs 
MUFA 
36 int, 35 
cont 
0.5 years 
OmegaAD – Freund-
Levi 2008 (49) 
People with mild to moderate 
Alzheimer's disease, Sweden 
EPA & DHA supplement, 0.60g/d 
EPA & 1.72g/d DHA 
LCn3 vs n6 103 int, 101 
cont 
0.5 years 
OMEGA – Rauch 
2010(50) 
People who have had an acute 
myocardial infarction, Germany 
EPA & DHA supplement, 0.46g/d 
EPA & 0.39g/d DHA 
LCn3 vs 
MUFA 
1940 int, 
1911 cont 
1 year 
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OPAL – Dangour 
2010(51) 
Healthy cognitively normal adults 
aged 70-79, UK 
EPA & DHA supplement, 0.20g/d 
EPA & 0.50g/d DHA 
LCn3 vs 
MUFA 
434 int, 433 
cont 
1 year 
Palma 2015(52) People with schizophrenia, Spain EPA & DHA supplement, 0.84g/d 
EPA & 0.47g/d DHA 
LCn3 vs nil 30 int, 30 
cont 
1 year 
Pomponi 2014(53) Adults with mild to moderate 
Parkinson's disease (some with 
depression), Italy 
EPA & DHA supplement, 0.29g/d 
EPA & 0.80g/d DHA 
LCn3 vs n6 12 int, 12 
cont 
0.5 years 
Pratt 2009(54) Adults with paroxysmal or 
persistent atrial fibrillation, USA 
EPA & DHA supplement, 1.86g/d 
EPA & 1.5g/d DHA 
LCn3 vs n6 332 int, 331 
cont 
0.5 years 
PREDIMED – Estruch 
2013(62) 
Men aged 55 to 80 years and 
women aged 60 to 80 years, free 
of CVD but with diabetes or at 
least 3 CVD risk factors, Spain 
Dietary advice and food 
supplement (mixed nuts), PUFA 
dose unclear 
PUFA vs 
MUFA 
2454 int, 
2543 cont 
5 years 
Sinn 2012(55) Older people with mild cognitive 
impairment & few comorbidities, 
Australia 
EPA & DHA supplement, 1.67g/d 
EPA & 0.16g/d DHA or 0.4g/d 
EPA & 1.55g/d DHA 
LCn3 vs n6 36 int, 18 
cont 
0.5 years 
SUFOLOM3 – Galan 
2010(56) 
People with a history of MI, 
unstable angina or ischemic 
stroke, France 
EPA & DHA supplement, 0.4g/d 
EPA & 0.2g/d DHA 
LCn3 vs non-
fat 
1248 int, 
1253 cont 
4 years 
Tajalizadekhoob 
2011(28) 
Elderly poor people with mild or 
moderate depression, Iran 
EPA & DHA supplement, 0.18g/d 
EPA & 0.12g/d DHA 
LCn3 vs 
mixed fat 
33 int, 33 
cont 
0.5 years 
THIS DIET – Tuttle 
2008(57) 
Survivors of recent first myocardial 
infarction, USA 
LCn3 dietary advice, dose unclear  LCn3 vs 
mixed fat 
51 int, 50 
cont 
2 years 
32 
 
TREND-HD 2008(58) People with Huntington's disease, 
USA & Canada 
EPA supplement, 0.95g/d EPA LCn3 vs non-
fat 
158 int, 158 
cont 
0.5 years 
Table 1: Brief characteristics of included studies (see Supplementary Table 1 for further details) 
 
